{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-002086","form_type":"8-K","ticker":"MRKR","cik":"0001094038","company_name":"Marker Therapeutics, Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.346345+00:00","generated_at":"2026-06-07T01:58:11.085231+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Marker Therapeutics prioritizes MT-601 for CAR T-relapsed lymphoma, discontinues patient-specific AML program","bullets":["MT-601 for DLBCL patients who relapsed after CAR T: first APOLLO participant maintained complete response at 6 months.","Patient-specific AML program (ARTEMIS) discontinued due to manufacturing delays; shift to ready-to-use MT-401 from healthy donors.","Non-dilutive funding secured for off-the-shelf AML program; cash runway extended into Q4 2025.","Pancreatic cancer Phase 1 IND cleared but advancement pending additional non-dilutive funding.","MultiTAA T cell therapies shown safe in over 200 patients; no treatment-related adverse events in APOLLO or ARTEMIS."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-002086","json":"https://secwatch.observer/filing/0001104659-24-002086.json","markdown":"https://secwatch.observer/filing/0001104659-24-002086.md","text":"https://secwatch.observer/filing/0001104659-24-002086.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1094038/000110465924002086/0001104659-24-002086-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1094038/000110465924002086/tm242285d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T01:58:11.085231+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}